NeoGenomics (NASDAQ:NEO) Announces Quarterly Earnings Results

NeoGenomics (NASDAQ:NEO) released its earnings results on Tuesday. The medical research company reported ($0.02) EPS for the quarter, missing the consensus estimate of $0.03 by ($0.05), Zacks reports. NeoGenomics had a negative net margin of 12.07% and a negative return on equity of 2.11%.

NeoGenomics Stock Down 14.0 %

NASDAQ NEO opened at $12.40 on Wednesday. The company has a current ratio of 1.99, a quick ratio of 1.91 and a debt-to-equity ratio of 0.37. The company has a 50 day moving average price of $15.63 and a two-hundred day moving average price of $15.57. NeoGenomics has a 12-month low of $10.69 and a 12-month high of $19.11.

Analysts Set New Price Targets

Several equities analysts have commented on the stock. The Goldman Sachs Group lowered their target price on shares of NeoGenomics from $20.00 to $18.00 and set a “buy” rating on the stock in a research note on Tuesday, January 28th. Benchmark cut shares of NeoGenomics from a “buy” rating to a “hold” rating in a research note on Monday, January 13th. Jefferies Financial Group began coverage on shares of NeoGenomics in a research report on Tuesday, December 10th. They issued a “buy” rating and a $22.00 target price on the stock. Bank of America lifted their target price on shares of NeoGenomics from $18.00 to $19.00 and gave the stock a “neutral” rating in a research report on Friday, December 13th. Finally, Needham & Company LLC reissued a “buy” rating and issued a $19.00 target price on shares of NeoGenomics in a research report on Friday, January 10th. Two equities research analysts have rated the stock with a hold rating and nine have given a buy rating to the company’s stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus price target of $20.20.

About NeoGenomics

NeoGenomics, Inc operates a network of cancer-focused testing laboratories in the United States and the United Kingdom. It operates through Clinical Services and Advanced Diagnostics segments. The company offers testing services to hospitals, academic centers, pathologists, oncologists, clinicians, pharmaceutical companies, and clinical laboratories.